Skip to main content
. 2017 Jan 23;17:70. doi: 10.1186/s12885-017-3065-3

Fig. 3.

Fig. 3

Impact of tumoral CCR7 expression on patients’ best drug response for tyrosine kinase inhibitors and PFS. a Patients’ best drug response according to tumoral CCR7 expression; b PFS according to tumoral CCR7 expression; c Heng’s risk model expanded with tumoral CCR7 expression